|
|
Blood, 26 March 2009, Vol. 113, No. 13, pp. 2934-2944.
Prepublished online as a Blood First Edition Paper on January 9, 2009; DOI 10.1182/blood-2008-09-181164.
Previous Article | Next Article 
Submitted September 29, 2008
Accepted December 27, 2008
SHIP limits immunoregulatory capacity in the T cell compartment
Michelle M. Collazo, Daniela Wood, Kim H.T. Paraiso, Erin Lund, Robert W. Engelman, Cam-Tien Le, Diana Stauch, Katja Kotsch, and William G. Kerr*
Immunology, Moffitt Comprehensive Cancer Center and Research Institute, Tampa, FL, United States
Pathology & Cell Biology, Moffitt Comprehensive Cancer Center and Research Institute, Tampa, FL, United States
Universitat Charite, Berlin, Germany
* Corresponding author; email: william.kerr{at}moffitt.org.
Regulatory T cells (Tregs) play a pivotal role in preventing autoimmunity, GvHD and organ graft rejection. We previously showed that either germline or induced SHIP-deficiency in the host abrogates GvHD. Here we show that SHIP-deficiency promotes an increase of CD4+CD25+FoxP3+Tregs and CD4+CD25-FoxP3+ "naive" T cells in the periphery that display increased CD103, GITR, OX40 and Fc RII/III expression. SHIP-deficiency does not compromise Treg function since SHIP-deficient CD3+CD4+CD25+Tregs are as suppressive as WT CD3+CD4+CD25+Treg. Interestingly, like conventional Tregs, SHIP-/- CD4+CD25-T cells are unresponsive to MHC-mismatched stimulators and suppress allogeneic responses by T cells in vitro. In addition, SHIP-/- CD4+CD25-T cells mediate reduced lethal GvHD upon adoptive transfer to MHC-mismatched hosts. Furthermore, hosts with induced SHIP-deficiency exhibit delayed rejection of MHC-mismatched cardiac grafts. Thus, SHIP is required for robust GvH and HvG responses by CD4+T cell and limits their immunoregulatory capacity. These findings further define the immunosuppressive mechanisms that result from SHIP-deficiency and provide additional justification for targeting SHIP in clinical transplantation.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Peng, P. Ye, D. J. Rawlings, H. D. Ochs, and C. H. Miao
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy
Blood,
November 12, 2009;
114(20):
4373 - 4382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nagaraj, M. Collazo, C. A. Corzo, J.-I. Youn, M. Ortiz, D. Quiceno, and D. I. Gabrilovich
Regulatory Myeloid Suppressor Cells in Health and Disease
Cancer Res.,
October 1, 2009;
69(19):
7503 - 7506.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. R. Locke, S. J. Patterson, M. J. Hamilton, L. M. Sly, G. Krystal, and M. K. Levings
SHIP Regulates the Reciprocal Development of T Regulatory and Th17 Cells
J. Immunol.,
July 15, 2009;
183(2):
975 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|